PDGF Receptor alpha (PDGFRA) Human shRNA Lentiviral Particle (Locus ID 5156)

CAT#: TL310535V

PDGFRA - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL310535A virus into HEK293 cells. TL310535A virus was prepared using lenti-shRNA TL310535A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL310535B virus into HEK293 cells. TL310535B virus was prepared using lenti-shRNA TL310535B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL310535C] virus into HEK293 cells. [TL310535C] virus was prepared using lenti-shRNA [TL310535C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL310535D] virus into HEK293 cells. [TL310535D] virus was prepared using lenti-shRNA [TL310535D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 5156
• Synonyms: CD140A; PDGFR-2; PDGFR2
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_006206, NM_001347827, NM_001347828, NM_001347829, NM_001347830, NM_006206.1, NM_006206.2, NM_006206.3, NM_006206.4, NM_006206.5, BC015186, BC063414
• UniProt ID: P16234
• Summary: This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers. [provided by RefSeq, Mar 2012]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).